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Abstract Celiac disease is caused by an abnormal intestinal
T-cell response to gluten proteins of wheat, barley and rye.
Over the last few years, a number of gluten T-cell epitopes
restricted by celiac disease associated HLA-DQ molecules
have been characterized. In this work, we give an overview
of these epitopes and suggest a comprehensive, new
nomenclature.
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HLA-DQ2.HLA-DQ8
Celiac disease (CD) is caused by an abnormal intestinal
immune response to proline and glutamine-rich wheat glu-
ten proteins and to similar proteins in barley and rye (Green
and Cellier 2007). Oat is generally considered safe for
consumption by CD patients (Garsed and Scott 2007), al-
though some patients appear to be sensitive to oat as well
(Lundin et al. 2003). The only established treatment for the
disease is a lifelong gluten exclusion diet.
CD has a strong HLA association. The most prominent
association is with HLA-DQ2.5 (DQA1*05:01,
DQB1*02:01) (Table 1). In individuals who carry the
DR3DQ2 haplotype, this molecule is encoded by DQA1 and
DQB1 alleles located on the same chromosome (in cis config-
uration), whereas in individuals who are DR5DQ7/DR7DQ2
heterozygous it is encoded by alleles located on opposite
chromosomes (trans configuration) (Sollid et al. 1989). Most
of the remaining patients carry DR4DQ8 haplotypes, and in
these patients it is the DQ8 molecule encoded by DQA1*03,
DQB1*03:02 that is involved in the pathogenesis (Lundin et
al. 1994). In the small remaining population of CD patients
that are neither DQ2.5 or DQ8, the patients typically express
HLA-DQ molecules that contain ‘half’ of DQ2.5 molecule as
they areeither DQ2.2 (DQA1*02:01, DQB1*02:01) or DQ7.5
(DQA1*05, DQB1*03:01) (Karell et al. 2003). As both the
DQA1 and DQB1 loci are polymorphic, unique HLA-DQ
molecules can be encoded in trans configuration. Examples
of such molecules are DQ2.3 (DQA1*03, DQB1*02:01) and
DQ8.5 (DQA1*05, DQB1*03:02) found in DR3DQ2/
DR4DQ8 heterozygous individuals (Table 1).
CD4
+ T cells of CD patients (Lundin et al. 1993), but not
healthy subjects (Molberg et al. 1997), recognize gluten pep-
tides when presented by disease associated HLA-DQ mole-
cules. This was first shown for DQ2.5 and DQ8 (Lundin et al.
1994), and recently it was demonstrated that DQ2.2 patients
(Boddetal.2012)andapatientwhocarriesDQ8.5inararecis
configuration (Kooy-Winkelaar et al. 2011)a l s oh a v eg l u t e n -
reactive T cells in the intestinal mucosa. Gluten-reactive T
cells can readily be established from intestinal biopsies cul-
tured in vitro (Camarca et al. 2009; Lundin et al. 1993, 1994;
Tye-Din et al. 2010; Vader et al. 2002b;v a nd eW a le ta l .
1998b). T cells recognizing the same gluten epitopes are
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DOI 10.1007/s00251-012-0599-znormally not detected in the peripheral blood (Anderson et al.
2000), but can be found in the blood of treated CD patients on
day 6 after a 3-day oral gluten challenge (Anderson et al.
2000, 2005;R á k ie ta l .2007).
HLA is the most important genetic factor in CD, and
carriage of certain HLA alleles is a necessary, but not
sufficient, factor for disease development (Sollid 2002).
The other factors required for disease development are
non-HLA genes, of which 39 loci have been identified
so far (Trynka et al. 2011), and possibly environmental
factors other than gluten. To note, mice transgenic for
HLA-DQ2.5 and gluten specific T-cell receptors do not
develop a CD-like enteropathy (de Kauwe et al. 2009;
Du Pre et al. 2011). The reason why these mice do not
develop enteropathy may relate to fundamental differ-
ences in the gut physiology between mouse and man,
and to the lack of appropriate non-MHC genes in the
mouse strains tested that parallel the non-HLA suscep-
tibility genes of CD patients.
The differential risk of DQ2.5 and DQ2.2 is linked with
the T-cell response to gluten. It has been demonstrated that
DQ2.5 binds a larger gluten peptide repertoire compared to
DQ2.2 (Vader et al. 2003b). Further, gluten T-cell epitopes
form stable complexes with DQ2.5, and the increased risk of
DQ2.5 over DQ2.2 correlates with a different ability of the
two HLA molecules to form stable complexes with many
gluten peptides (Fallang et al. 2009).
Characteristically, gluten-reactive T cells of CD patients
recognize their antigenic peptides much better when specific
glutamine residues are converted to glutamate by the enzyme
transglutaminase 2 (TG2) (Molberg et al. 1998; van de Wal et
al. 1998a). Deamidated gluten peptides bind with increased
affinity to DQ2.5 and DQ8 (Arentz-Hansen et al. 2000;
Camarca et al. 2009; Henderson et al. 2007; Kim et al.
2004; Moustakas et al. 2000; Quarsten et al. 1999), and the
rateofdissociationofdeamidatedglutenpeptidesfromDQ2.5
has been shown tobe substantially slower thanfor their native
counterparts (Xia et al. 2005). The ability to form stable
peptide–MHC complexes again seems to be a key factor for
the initiation of the anti-gluten T-cell response.
Gluten is defined as the cohesive mass that remains
when dough is washed to remove starch (Shewry et al.
1992). Traditionally and strictly speaking, gluten is a
name of wheat proteins only, but gluten is now increas-
ingly used as a term to denote proline- and glutamine-
rich proteins of wheat, barley, rye and oat. In wheat,
gluten consists of the gliadin and glutenin subcompo-
nents. The gliadin proteins can be subdivided into α-,
γ-a n dω-gliadins, while the glutenin proteins can be
s u b d i v i d e di n t oh i g hm o l e c u l a rw e i g h t( H M W )a n dl o w
molecular weight (LMW) subunits. Common bread
wheat is a hexaploid species, and in addition some of
the gluten protein encoding genes originate from dupli-
cated loci. Thus, in a single wheat variety there exits up
to several hundred different gluten proteins, many of
which only differ by a few amino acids. The proline- and
glutamine-rich proteins of barley, rye and oat are termed
hordeins, secalins and avenins, respectively.
Given the heterogeneity of the wheat gluten proteins,
it is no surprise that many distinct gliadin and glutenin
derived T-cell epitopes exist (Table 2). T-cell epitopes
derived from either α-, γ-, and ω-gliadins as well as
from HMW and LMW glutenins have been reported
(Arentz-Hansen et al. 2000;S j ö s t r ö me ta l .1998; Vader
et al. 2002b;v a nd eW a le ta l .1998b). T-cell epitopes
in both hordeins and secalins have been described and
they are highly homologous to those found in wheat
(Tye-Din et al. 2010; Vader et al. 2003a). The avenins
of oat are more distinct, and although oat is considered
safe for CD patients (Garsed and Scott 2007), some CD
patients are clinically sensitive to oat (Lundin et al.
2003). Avenin specific as well as cross-reactive responses
have been described (Arentz-Hansen et al. 2004; Vader et al.
2003a).
There is at present no standard nomenclature for CD-
relevant gluten epitopes. Here, we propose such a nomen-
clature based on the following three criteria:
1. Reactivity against the epitope must have been defined
by at least one specific T-cell clone.
Table 1 Description and nam-
ing of HLA-DQ molecules that
are associated with celiac disease
and which are used as antigen
presenting elements for CD4
+ T
cells of celiac disease patients
aRisk for celiac disease has not
been established in population
studies
bMolecule can also be encoded
in cis on some rare haplotypes
Encoded by Risk for celiac
disease
Expression in cis
or trans position
Part of common
cis haplotype
HLA-DQ molecule DQA1* DQB1*
HLA-DQ2.5 05 02 High cis, trans DR3DQ2
HLA-DQ2.2 02 02 Low cis, (trans) DR7DQ2
HLA-DQ2.3 03 02 Likely low
a trans, (cis)
b
HLA-DQ7.5 05 03:01 Very low cis, (trans) DR5DQ7
HLA-DQ8 03 03:02 Low cis DR4DQ8
HLA-DQ8.5 05 03:02 Likely low
a trans, (cis)
b
456 Immunogenetics (2012) 64:455–4602. The HLA-restriction element involved must have been
unequivocally defined.
3. The nine-amino acid core of the epitope must have been
defined either by an analysis with truncated peptides
and/or HLA-binding with lysine scan of the epitope or
comparable approach.
Searching the literature using these criteria, we have
compiled a list of epitopes (Table 2). This list includes
sequences from α-gliadin, γ-gliadin, ω-gliadin, LMW-
and HMW-glutenins, hordeins, secalins and avenins. To
note, most gluten-reactive T cells have minimal epitopes
longer than those listed in Table 2. This is because MHC
Table 2 List of celiac disease relevant T-cell epitopes recognized by CD4
+ T cells
Epitope
a Previous names Peptide-binding register
b Reference
123456789
DQ2.5 restricted epitopes
DQ2.5-glia-α1a DQ2-α-I, α9 PFPQPE L P Y (Arentz-Hansen et al. 2000)
DQ2.5-glia-α1b DQ2-α-III P Y P Q P E L P Y (Arentz-Hansen et al. 2002)
DQ2.5-glia-α2 DQ2-α-II, α2P Q P E L P Y P Q (Arentz-Hansen et al. 2000)
DQ2.5-glia-α3 glia-α20 F R P E Q P Y P Q (Vader et al. 2002b)
DQ2.5-glia-γ1 DQ2-γ- I PQQSFPE Q Q (Sjöström et al. 1998)
DQ2.5-glia-γ2 DQ2-γ-II, γ30 I Q P E Q P A Q L (Qiao et al. 2005; Vader et al. 2002b)
DQ2.5-glia-γ3 DQ2-γ-III QQPE QPYPQ (Arentz-Hansen et al. 2002)
DQ2.5-glia-γ4a DQ2-γ-IV S Q P E Q E F P Q (Arentz-Hansen et al. 2002)
DQ2.5-glia-γ4b DQ2-γ-VIIc P Q P E Q E F P Q (Qiao et al. 2005)
DQ2.5-glia-γ4c DQ2-γ-VIIa QQPE Q P F P Q (Arentz-Hansen et al. 2002)
DQ2.5-glia-γ4d DQ2-γ-VIIb P Q P E QPFCQ (Qiao, unpublished)
DQ2.5-glia-γ5 DQ2-γ-VI Q Q P F P E Q P Q (Arentz-Hansen et al. 2002)
DQ2.5-glia-ω1 DQ2-ω- I PFPQPE Q P F (Tye-Din et al. 2010)
DQ2.5-glia-ω2 DQ2-ω-II P Q P E Q P F P W (Tye-Din et al. 2010)
DQ2.5-glut-L1 glutenin-17 P F S E Q E Q P V (Vader et al. 2002b)
DQ2.5-glut-L2 glutenin-156 F S QQQE S P F (Stepniak et al. 2005; Vader et al. 2002b)
DQ2.5-hor-1 Hor-α9, Hα9 PFPQPE Q P F (Tye-Din et al. 2010; Vader et al. 2003a)
DQ2.5-hor-2 Hor-α2, Hα2P Q P E Q P F P Q (Vader et al. 2003a)
DQ2.5-hor-3 hor-I-DQ2 P I P E Q P Q P Y (Tye-Din et al. 2010)
DQ2.5-sec-1 Sec-α9, Sα9 PFPQPE Q P F (Tye-Din et al. 2010; Vader et al. 2003a)
DQ2.5-sec-2 Sec-α2, Sα2P Q P E Q P F P Q (Vader et al. 2003a)
DQ2.5-ave-1a Av-α9A P Y P E Q E E P F (Arentz-Hansen et al. 2004; Vader et al. 2003a)
DQ2.5-ave-1b Av-α9B, 1490 P Y P E Q E Q P F (Arentz-Hansen et al. 2004; Vader et al. 2003a)
DQ2.2 restricted epitopes
DQ2.2-glut-L1 glutenin-17 P F S E Q E Q P V (Bodd et al. 2012)
DQ8 restricted epitopes
DQ8-glia-α1 DQ8-α-I E GSFQPSQE (van de Wal et al. 1998b)
DQ8-glia-γ1a DQ8-γ-Ia E QPQ Q P F P Q (Tollefsen et al. 2006)
DQ8-glia-γ1b DQ8-γ-Ib E QPQQPYPE (Tollefsen et al. 2006)
DQ8-glut-H1 HMW-glutenin QGYYPTSPQ (van de Wal et al. 1999)
DQ8.5 restricted epitopes
DQ8.5-glia-α1 DQ8-α-I E GSFQPSQE (Kooy-Winkelaar et al. 2011)
DQ8.5-glia-γ1 PQQSFPE Q E (Kooy-Winkelaar et al. 2011)
DQ8.5-glut-H1 HMW-glutenin QGYYPTSPQ (Kooy-Winkelaar et al. 2011)
aIn the epitope names, these short terms are used to denote the type of proteins that the epitopes derive from: ‘glia-α’ denotes α-gliadin, ‘glia-γ’
denotes γ-gliadin, ‘glia-ω’ denotes ω-gliadin, ‘glut-L’ denotes low molecular weight glutenin, ‘glut-H’ denotes high molecular weight glutenin,
‘hor’ denotes hordein, ‘sec’ denotes secalin and ‘ave’ denotes avenin
bGlutamate residues (E) formed by TG2-medited deamidation which are important for recognition by T cells are shown in bold. Additional
glutamine residues also targeted by TG2 are underlined
Immunogenetics (2012) 64:455–460 457class II restricted T-cell receptors usually are sensitive to a
few residues flanking the nine-amino acid core region of the
epitopes.
In Table 2, some sequences that previously were defined
as individual epitopes have been grouped together as mem-
bers of the same family. This pertains to the DQ2.5-glia-α1a
and DQ2.5-glia-α1b as well as the DQ2.5-glia-γ4a, DQ2.5-
glia-γ4b, DQ2.5-glia-γ4c and DQ2.5-glia-γ4d epitopes.
The reason is that the sequences defining these epitopes
are very similar, although there are occasionally T-cell
clones that can distinguish between members of the same
epitope family (Arentz-Hansen et al. 2002;Q i a oe ta l .
2005). Most T-cell clones appear to cross-react between
peptide sequences of the same family.
The nine-amino acid core sequences of some of the DQ2.5
restricted epitopes are identical, but because these epitopes
derive from different cereal species they are still listed as
unique epitopes. This applies to the DQ2.5-glia-ω1, DQ2.5-
hor-1 and DQ2.5-sec-1 epitopes, as well as DQ2.5-hor-2 and
DQ2.5-sec-2epitopes.T-cellcross-reactivitybetweenproteins
ofdifferentspecieshencedoesoftenoccur,butTcellsreactive
with these epitopes can also be species-specific as the T-cell
receptors may be sensitive to unique residues flanking the
nine-amino acid core region of the epitopes. In addition, there
areepitopes,likeDQ2.5-hor-3(Tye-Dinetal.2010),thathave
sequences which are hordein or secalin specific and which
elicit species specific T-cell responses.
The majority of gluten-reactive T cells generated from
DQ2.5 positive CD patients can recognize their epitopes when
confronted in vitro with antigen presenting cells expressing the
closely related HLA-DQ2.2 molecule (DQA1*02:01,
DQB1*02:01). Yet, DQ2.2 positive CD patients do not
mount a T-cell response to the same gluten epitopes,
but rather have responses to gluten peptides that bind stably
to DQ2.2 (Bodd et al. 2012). When defining an epitope, it is
thus important to assess and categorize the epitope only in the
context of the HLA molecules that are expressed by the T-cell
donor.
The selection of gluten T-cell epitopes is best understood
in HLA-DQ2.5 positive CD patients, and is influenced by at
least three factors: (a) resistance of the polypeptide sequence
to proteolytic degradation, (b) specificity of TG2 and (c)
HLA binding specificity. The proline-rich nature of gluten
makes the gluten proteins resistant to proteolytic degrada-
tion in the gastrointestinal lumen, and long gluten peptide
fragments ranging from 15 to 50 residues therefore survive
in the small intestine (Shan et al. 2002). T-cell epitopes are
often localized within such long fragments (Arentz-Hansen
et al. 2002). The resulting proline and glutamine rich pep-
tides are often good substrates for TG2 (Dørum et al. 2009,
2010; Fleckenstein et al. 2002; Vader et al. 2002a). Proline
is influencing the specificity of TG2 as the enzyme typically
recognizes glutamine residues in glutamine-X-proline
sequences (Fleckenstein et al. 2002; Vader et al. 2002a).
T-cell epitopes in their native form are usually very good
substrates for TG2. TG2, being an important factor in the
selection of T-cell epitopes, is demonstrated by the fact that
TG2 is selectively targeting peptides which harbor T-cell
epitopes from a digest of gluten with extreme complexity
(Dørum et al. 2010). Finally, determinant selection by
MHC is influencing repertoire of T-cell epitopes. In
general, gluten peptides are poor binders to HLA class
II molecules with the exception of HLA-DQ molecules
associated with CD (Bergseng et al. 2008). Some gluten
peptides also bind HLA-DR53 (Clot et al. 1999), although so
far no Tcells of celiac lesions recognizing these peptides have
been described. The selective force of HLA is illustrated by
the observation that the DQ2.5 and DQ8 epitopes generally
come from non-overlapping sequences of gluten proteins
(Tollefsen et al. 2006).
The glutamate introduced by TG2 is usually in position 4
(P4), P6 or P7 in HLA-DQ2.5 restricted epitopes and at
position P1 and/or P9 in HLA-DQ8 restricted epitopes
(Table 2). These glutamate residues serve as anchor residues
important for binding of the peptides. Both HLA-DQ2.5 and
DQ8 prefer negatively charged residues at these anchors
sites. This positioning of deamidated glutamine residues is
strongly related to the positioning of proline residues, which
is particularly strict in the case of DQ2.5 epitopes, as DQ2.5
only accepts proline at certain position in the peptide bind-
ing groove (Kim et al. 2004). This results in a dominant
presence of proline at P1, P6 and P8 and leads to the
modification by TG2 of the glutamine residues at P4 and
P6, respectively. Such positioning of proline residues is less
strict in the case of the DQ8 epitopes. Although polyclonal
T-cell responses to multiple T-cell epitopes are almost inva-
riably found in CD patients, responses to the DQ2.5-glia-
α1a, DQ2.5-glia-α1b, DQ2.5-glia-α2 epitopes, DQ2.5-glia-
ω1, DQ2.5-glia-ω2, DQ2.5-hor-1 and DQ2-sec-1 are dom-
inant in DQ2.5 positive patients (Arentz-Hansen et al. 2000;
Camarca et al. 2009; Tollefsen et al. 2006; Tye-Din et al.
2010). In DQ8-positive patients, responses to the DQ8-glia-
α1 epitope are most frequently found (Tollefsen et al. 2006;
van de Wal et al. 1998b).
The list of gluten epitopes recognized by T cells of CD
patients presented in Table 2 will be extended as new
epitopes become known in the future. A dedicated website
(http://www.isscd.org/EpitopeNomenclature) will update
this list as more epitopes are identified.
Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use,
distribution, and reproduction in any medium, provided the original
author(s) and the source are credited.
458 Immunogenetics (2012) 64:455–460References
Anderson RP, Degano P, Godkin AJ, Jewell DP, Hill AV (2000)
In vivo antigen challenge in celiac disease identifies a single
transglutaminase-modified peptide as the dominant A-gliadin T-cell
epitope. Nat Med 6:337–342
Anderson RP, van Heel DA, Tye-Din JA, Barnardo M, Salio M, Jewell
DP, Hill AV (2005) Tcellsinperipheralbloodafterglutenchallenge
in coeliac disease. Gut 54:1217–1223
Arentz-Hansen H, Körner R, Molberg QH, Vader W, Kooy YM,
Lundin KEA, Koning F, Roepstorff P, Sollid LM, McAdam SN
(2000) The intestinal T cell response to α-gliadin in adult celiac
disease is focused on a single deamidated glutamine targeted by
tissue transglutaminase. J Exp Med 191:603–612
Arentz-Hansen H, McAdam SN, Molberg FB, Lundin KE, Jorgensen
TJ, Jung G, Roepstorff P, Sollid LM (2002) Celiac lesion T cells
recognize epitopes that cluster in regions of gliadins rich in proline
residues. Gastroenterology 123:803–809
Arentz-Hansen H, Fleckenstein B, Molberg SH, Koning F, Jung G,
Roepstorff P, Lundin KE, Sollid LM (2004) The molecular basis
for oat intolerance in patients with celiac disease. Plos Med 1:e1
Bergseng E, Sidney J, Sette A, Sollid LM (2008) Analysis of the
binding of gluten T-cell epitopes to various human leukocyte
antigen class II molecules. Hum Immunol 69:94–100
Bodd M, Kim CY, Lundin KE, Sollid LM (2012) Characterization of
the T-cell reponse to gluten in patients with celiac disease express-
ing HLA-DQ2.2 but not any other HLA-DQ risk molecules.
Gastroenterology, in press
CamarcaA,AndersonRP,MamoneG,FierroO,FacchianoA,Costantini
S,ZanziD,SidneyJ,AuricchioS,SetteA,TronconeR,GianfraniC
(2009) Intestinal T cell responses to gluten peptides are largely
heterogeneous: implications for a peptide-based therapy in celiac
disease. J Immunol 182:4158–4166
Clot F, Gianfrani C, Babron MC, Bouguerra F, Southwood S, Kagnoff
MF, Troncone R, Percopo S, Eliaou JF, Clerget-Darpoux F, Sette
A, Greco L (1999) HLA-DR53 molecules are associated with
susceptibility to celiac disease and selectively bind gliadin-derived
peptides. Immunogenetics 49:800–807
de Kauwe AL, Chen Z, Anderson RP, Keech CL, Price JD, Wijburg O,
Jackson DC, Ladhams J, Allison J, McCluskey J (2009) Resis-
tance to celiac disease in humanized HLA-DR3-DQ2-transgenic
mice expressing specific anti-gliadin CD4
+ T cells. J Immunol
182:7440–7450
Dørum S, Qiao SW, Sollid LM, Fleckenstein B (2009) A quantitative
analysis of transglutaminase 2-mediated deamidation of gluten
peptides: implications for the T-cell response in celiac disease. J
Proteome Res 8:1748–1755
Dørum S, Arntzen MO, Qiao SW, Holm A, Koehler CJ, Thiede B,
Sollid LM, Fleckenstein B (2010) The preferred substrates for
transglutaminase 2 in a complex wheat gluten digest are peptide
fragments harboring celiac disease T-cell epitopes. PLoS One 5:
e14056
Du Pre MF, Kozijn AE, van Berkel LA, ter Borg MN, Lindenbergh-
Kortleve D, Jensen LT, Kooy-Winkelaar Y, Koning F, Boon L,
Nieuwenhuis EE, Sollid LM, Fugger L, Samsom JN (2011) Tol-
erance to ingested deamidated gliadin in mice is maintained by
splenic, type 1 regulatory Tcells. Gastroenterology 141:610–620,
620 e1–e2
Fallang LE, Bergseng E, Hotta K, Berg-Larsen A, Kim CY, Sollid LM
(2009) Differences in the risk of celiac disease associated with
HLA-DQ2.5 or HLA-DQ2.2 are related to sustained gluten antigen
presentation. Nat Immunol 10:1096–10101
Fleckenstein B, Molberg QSW, Schmid DG, Von Der MF, Elgstoen K,
Jung G, Sollid LM (2002) Gliadin T cell epitope selection by
tissue transglutaminase in celiac disease. Role of enzyme
specificity and pH influence on the transamidation versus deami-
dation process. J Biol Chem 277:34109–34116
Garsed K, Scott BB (2007) Can oats be taken in a gluten-free diet? A
systematic review. Scand J Gastroenterol 42:171–178
Green PH, Cellier C (2007) Celiac disease. N Engl J Med 357:1731–
1743
Henderson KN, Tye-Din JA, Reid HH, Chen Z, Borg NA, Beissbarth
T, Tatham A, Mannering SI, Purcell AW, Dudek NL, van Heel
DA, McCluskey J, Rossjohn J, Anderson RP (2007) A structural
and immunological basis for the role of human leukocyte antigen
DQ8 in celiac disease. Immunity 27:23–34
Karell K, Louka AS, Moodie SJ, Ascher H, Clot F, Greco L, Ciclitira
PJ, Sollid LM, Partanen J (2003) HLA types in celiac disease
patients not carrying the DQA1*05-DQB1*02 (DQ2) heterodimer:
results from the European Genetics Cluster on Celiac Disease. Hum
Immunol 64:469–477
Kim CY, Quarsten H, Bergseng E, Khosla C, Sollid LM (2004)
Structural basis for HLA-DQ2-mediated presentation of gluten
epitopes in celiac disease. Proc Natl Acad Sci U S A 101:4175–
4179
Kooy-Winkelaar Y, van Lummel M, Moustakas AK, Schweizer J,
Mearin ML, Mulder CJ, Roep BO, Drijfhout JW, Papadopoulos
G, van Bergen J, Koning F (2011) Gluten-specific T cells cross-
react between HLA-DQ8 and the HLA-DQ2α/DQβ transdimer. J
Immunol 187:5123–5129
Lundin KEA, Scott H, Hansen T, Paulsen G, Halstensen TS, Fausa O,
Thorsby E, Sollid LM (1993) Gliadin-specific, HLA-DQ
(α1*0501, β1*0201) restricted T cells isolated from the small
intestinal mucosa of celiac disease patients. J Exp Med 178:187–
196
Lundin KEA, Scott H, Fausa O, Thorsby E, Sollid LM (1994) T cells
from the small intestinal mucosa of a DR4, DQ7/DR4, DQ8 celiac
disease patient preferentially recognize gliadin when presented by
DQ8. Hum Immunol 41:285–291
Lundin KEA, Nilsen EM, Scott HG, Løberg EM, Gjøen A, Bratlie J,
Skar V, Mendez E, Løvik A, Kett K (2003) Oats induced villous
atrophy in coeliac disease. Gut 52:1149–1152
Molberg O, Kett K, Scott H, Thorsby E, Sollid LM, Lundin KEA
(1997) Gliadin specific, HLA DQ2-restricted Tcells are commonly
found in small intestinal biopsies from coeliac disease patients, but
not from controls. Scand J Immunol 46:103–109
Molberg O, McAdam SN, Körner R, Quarsten H, Kristiansen C,
Madsen L, Fugger L, Scott H, Roepstorff P, Lundin KEA, Sjöström
H, Sollid LM (1998) Tissue transglutaminase selectively modifies
gliadin peptides that are recognized by gut-derived Tcells. Nat Med
4:713–717
Moustakas AK, van de Wal Y, Routsias J, Kooy YM, Van Veelen P,
Drijfhout JW, Koning F, Papadopoulos GK (2000) Structure of
celiac disease-associated HLA-DQ8 and non-associated HLA-
DQ9 alleles in complex with two disease-specific epitopes. Int
Immunol 12:1157–1166
Qiao SW, Bergseng E, Molberg O, Jung G, Fleckenstein B, Sollid LM
(2005) Refining the rules of gliadin T cell epitope binding to the
disease-associated DQ2 molecule in celiac disease: importance of
proline spacing and glutamine deamidation. J Immunol 175:254–
261
Quarsten H, Molberg FL, McAdam SN, Sollid LM (1999) HLA
binding and T cell recognition of a tissue transglutaminase-
modified gliadin epitope. Eur J Immunol 29:2506–2514
Ráki M, Fallang LE, Brottveit M, Bergseng E, Quarsten H, Lundin KE,
Sollid LM (2007) Tetramer visualization of gut-homing gluten-
specific T cells in the peripheral blood of celiac disease patients.
Proc Natl Acad Sci U S A 104:2831–2836
Shan L, Molberg PI, Hausch F, Filiz F, Gray GM, Sollid LM, Khosla C
(2002)Structuralbasisforglutenintoleranceinceliacsprue.Science
297:2275–2279
Immunogenetics (2012) 64:455–460 459Shewry PR, Tatham AS, Kasarda DD (1992) Cereal proteins and
coeliac disease. In: Marsh MN (ed) coeliac disease. Blackwell
Scientific Publications, Oxford
Sjöström H, Lundin KEA, Molberg KR, McAdam SN, Anthonsen D,
Quarsten H, Noren O, Roepstorff P, Thorsby E, Sollid LM (1998)
Identification of a gliadin T-cell epitope in coeliac disease: general
importance of gliadin deamidation for intestinal T-cell recogni-
tion. Scand J Immunol 48:111–115
Sollid LM (2002) Coeliac disease: dissecting a complex inflammatory
disorder. Nat Rev Immunol 2:647–655
Sollid LM, Markussen G, Ek J, Gjerde H, Vartdal F, Thorsby E
(1989) Evidence for a primary association of celiac disease to
a particular HLA-DQ α/β heterodimer. J Exp Med 169:345–
350
Stepniak D, Vader LW, Kooy Y, van Veelen PA, Moustakas A,
Papandreou NA, Eliopoulos E, Drijfhout JW, Papadopoulos
GK, Koning F (2005) T-cell recognition of HLA-DQ2-bound
gluten peptides can be influenced by an N-terminal proline at p-1.
Immunogenetics 57:8–15
Tollefsen S, Arentz-Hansen H, Fleckenstein B, Molberg RM, Kwok
WW, Jung G, Lundin KE, Sollid LM (2006) HLA-DQ2 and -DQ8
signatures of gluten Tcell epitopes in celiac disease. J Clin Invest
116:2226–2236
Trynka G, Hunt KA, Bockett NA, Romanos J, Mistry V, Szperl A,
Bakker SF, Bardella MT, Bhaw-Rosun L, Castillejo G, de la
Concha EG, de Almeida RC, Dias KR, van Diemen CC, Dubois
PC, Duerr RH, Edkins S, Franke L, Fransen K, Gutierrez J, Heap
GA, Hrdlickova B, Hunt S, Izurieta LP, Izzo V, Joosten LA,
Langford C, Mazzilli MC, Mein CA, Midah V, Mitrovic M, Mora
B, Morelli M, Nutland S, Nunez C, Onengut-Gumuscu S, Pearce
K, Platteel M, Polanco I, Potter S, Ribes-Koninckx C, Ricano-
Ponce I, Rich SS, Rybak A, Santiago JL, Senapati S, Sood A,
Szajewska H, Troncone R, Varade J, Wallace C, Wolters VM,
Zhernakova A, Thelma BK, Cukrowska B, Urcelay E, Bilbao JR,
Mearin ML, Barisani D, Barrett JC, Plagnol V, Deloukas P,
Wijmenga C, van Heel DA (2011) Dense genotyping identifies
and localizes multiple common and rare variant association sig-
nals in celiac disease. Nat Genet 43:1193–1201
Tye-Din JA, Stewart JA, Dromey JA, Beissbarth T, van Heel DA,
Tatham A, Henderson K, Mannering SI, Gianfrani C, Jewell DP,
Hill AV, McCluskey J, Rossjohn J, Anderson RP (2010) Compre-
hensive, quantitative mapping of Tcell epitopes in gluten in celiac
disease. Sci Transl Med 2:41ra51
Vader LW, de Ru A, van Der WY, Kooy YM, Benckhuijsen W, Mearin
ML, Drijfhout JW, van Veelen P, Koning F (2002a) Specificity of
tissue transglutaminase explains cereal toxicity in celiac disease. J
Exp Med 195:643–649
Vader W, Kooy Y, van Veelen P, de Ru A, Harris D, Benckhuijsen W,
Pena S, Mearin L, Drijfhout JW, Koning F (2002b) The gluten
response in children with celiac disease is directed toward multi-
ple gliadin and glutenin peptides. Gastroenterology 122:1729–
1737
Vader LW, Stepniak DT, Bunnik EM, Kooy YM, de Haan W, Drijfhout
JW, van Veelen PA, Koning F (2003a) Characterization of cereal
toxicity for celiac disease patients based on protein homology in
grains. Gastroenterology 125:1105–1113
Vader W, Stepniak D, Kooy Y, Mearin L, Thompson A, van Rood JJ,
Spaenij L, Koning F (2003b) The HLA-DQ2 gene dose effect in
celiac disease is directly related to the magnitude and breadth of
gluten-specific T cell responses. Proc Natl Acad Sci U S A
100:12390–12395
van de Wal Y, Kooy Y, van Veelen P, Pena S, Mearin L, Papadopoulos
G, Koning F (1998a) Selective deamidation by tissue transgluta-
minase strongly enhances gliadin-specific T cell reactivity. J
Immunol 161:1585–1588
van deWalY, KooyYM, van VeelenPA, PenaSA, Mearin LM,Molberg
LKEA, Sollid LM, Mutis T, Benckhuijsen WE, Drijfhout JW,
Koning F (1998b) SmallintestinalTcellsofceliacdiseasepatients
recognizeanaturalpepsinfragmentofgliadin.ProcNatlAcadSciU
S A 95:10050–10054
van de Wal Y, Kooy YM, van Veelen P, Vader W, August SA, Drijfhout
JW, Pena SA, Koning F (1999) Glutenin is involved in the gluten-
driven mucosal T cell response. Eur J Immunol 29:3133–3139
Xia J, Sollid LM, Khosla C (2005) Equilibrium and kinetic analysis of
the unusual binding behavior of a highly immunogenic gluten
peptide to HLA-DQ2. Biochemistry 44:4442–4449
460 Immunogenetics (2012) 64:455–460